Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Core Insights - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The company’s lead candidate, ONP-002, is in Phase IIa clinical development for treating concussion and mild traumatic brain injury (mTBI), which affects approximately 69 million people globally each year without any approved pharmacological treatment [3] - The company received an unqualified audit opinion from its independent accounting firm regarding its financial statements, which included a paragraph about its ability to continue as a going concern [1] Financial Information - The audited consolidated financial statements for the fiscal year ended December 31, 2025, were filed on March 16, 2026, with the Securities and Exchange Commission [1][2] - The announcement regarding the audit opinion is made in compliance with NYSE American LLC Company Guide Section 610(b) [1] Company Overview - Oragenics is exploring the expansion of its central nervous system (CNS) pipeline strategy through both internal development and strategic business development [3] - The company’s intranasal delivery platform aims to provide rapid, non-invasive delivery of therapeutics directly to the brain, bypassing the blood-brain barrier [3]